Maria Vasiliki Benekou

Ms. Maria Vasiliki Benekou

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2026 in Onco
Verified
Journal Article
Open access
PDF file
Maria Vasiliki BenekouMaria Vasiliki Benekou
Maria Vasiliki Benekou
MLMarios Lampros
Marios Lampros
ALAikaterini Lianou
Aikaterini Lianou
PZPanagiota Zagorianakou
Panagiota Zagorianakou
Georgios D. LianosGeorgios D. Lianos
Georgios D. Lianos
George A. AlexiouGeorge A. Alexiou
George A. Alexiou
Cancer is a leading health issue worldwide, affecting approximately 20 million people annually. Developing efficient chemotherapy agents for cancer treatment is a challenging, costly, and time-consuming process. Drug repurposing for cancer treatment provides an optimal alternative, as the pharmacokinetic properties and the safety of these drugs have been previously tested. It also offers a faster and more cost-effective path to novel cancer therapies, which is especially valuable when conventional treatments face resistance or toxicity limitations. Antipsychotic drugs, which are primarily used for treating psychiatric disorders, including schizophrenia and bipolar disorder, have recently been investigated for their potential anticancer effects through drug repurposing strategies. While covering preliminary data and providing an overview of their mechanisms of action, this review highlights the latest research on antipsychotic medications’ emerging potential in oncology in experimental models, emphasizing their observed anticancer effects in preclinical studies, safety profile and capacity to enhance the effectiveness of conventional therapies. Despite growing interest, a research gap remains in translating these findings to clinical oncology, an issue this review addresses by proposing future investigative directions.

Verified
Journal Article
Open access
PDF file
Maria Vasiliki BenekouMaria Vasiliki Benekou
Maria Vasiliki Benekou
PTPanagiota Tzitiridou
Panagiota Tzitiridou
TPTheodora Papagrigoriou
Theodora Papagrigoriou
VGVasiliki Galani
Vasiliki Galani
Chrissa SiokaChrissa Sioka
Chrissa Sioka
George A. AlexiouGeorge A. Alexiou
George A. Alexiou
Glioblastoma (GMB) is a remarkably aggressive brain malignancy characterized by high mortality rates, despite continuous advances in therapeutic approaches. Compounds derived from plants are being studied for their potent medicinal properties in the quest for more efficient therapies. This study investigated the anti-glioma properties of Methyl rosmarinate, a hydroxycinnamic acid isolated from Thymus thracicus Velen, which has previously demonstrated anti-cancer activity in various cell lines. Human glioblastoma cell lines U87 and T98 were treated with Methyl rosmarinate to assess its effect on cell viability, cell cycle distribution and migratory capacity using Trypan blue assay, flow cytometry and scratch wound healing assay, respectively. The combinatorial effects of Methyl rosmarinate and temozolomide were also analyzed with CompoSyn software. According to the outcomes, Methyl rosmarinate significantly reduced cell viability, induced cell death by interfering in cell cycle checkpoints, and inhibited migration in both GMB cell lines. Notably, in U87 cells, the compound showed a synergistic impact with temozolomide, whereas in T98 cells, there was an antagonistic relationship. These results suggest that Methyl rosmarinate has potential anti-glioma properties; however, more in vivo research is needed.